anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban
DISEASE INTERVENTION COMPARISON RESULTS
Eur Heart J. 2018 Apr 21;39(16):1330-1393 Consensus, Guideline
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban The Use of
guidelines for their use in practice
As Treatment, Chronic
Is useful Than
no comparison here
To optimize their use and effectiveness, and avoid bleeding complications
Circulation. 2018 Feb 28. doi: 10.1161/CIRCULATIONAHA.117.031658. [Epub ahead of print] Cohorts
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, real-world data, very elderly patients The Use of
these 3 direct oral anticoagulants
As Treatment, Chronic
Is better Than
warfarin
To reduce the risk of intracranial bleeding (0.42 %/year DOAs VS 1.63 % warfarin) with similar effect in stroke and all-type major bleeding.
J Am Geriatr Soc. 2014 May;62(5):857-64 Meta-Analysis
IN atrial fibrillation, thromboembolic disease, old patients, anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban
As Treatment, Chronic
Is better Than
warfarin
To prevent stroke or VTE recurrence: no numbers given in abstract